Abstract:1378 Objectives: Diabetes is a risk factor for Parkinson9s disease. They share similar pathogenic pathways in mitochondrial dysfunction, endoplasmic reticulum stress, inflammation, and alterations in metabolism. However, the pathogenetic relationship between these two diseases is unclear. This study aimed to explore the relationship between VMAT2 and DAT expression in the striatum of T2DM rats. Methods: ZDF rats were used as T2DM animal models. T2DM and control rats were subjected to 18F-FP-(+)-DTBZ and 11C-CFT Micro-PET/CT static imaging at 3, 6 and 12 months of age. Results: The bodyweight of the two groups was statistically different at 6 months (P 0.05). The fasting blood glucose of the T2DM group at 6 months and 12 months (10.58 ± 3.00 mmol/L, 15.63 ± 5.85 mmol/ L) was significantly higher than the control group (5.95 ± 0.75 mmol/L, 5.40 ± 0.49 mmol/L) (P 0.05). There was a significant negative correlation between 18F-FP-(+)-DTBZ uptake and fasting blood glucose in the striatum of the two groups at 12 months (r2 = 0.753, P = 0.001). Conclusions: The increase of blood glucose caused by the decrease of BCM can decrease the expression of VMAT2 in the dopaminergic pathway in the brain. The expression of VMAT2 in the striatum of T2DM rats is also negatively correlated with fasting blood glucose. It is found that the abnormal expression of VMAT2 is earlier than DAT in the dopaminergic neurological abnormalities caused by T2DM. The extent is also heavier than DAT.

Establishment of Animal Model of Type 2 Diabetes and 18F-FP-(+)-DTBZ PET Imaging Study